SEC Form 4 · accession 0001140361-16-086264
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel K Spiegelman
Officer — EVP, Chief Financial Officer
Period of report
Oct 31, 2016
Accepted (ET)
Nov 14, 2016 · 2:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 31, 2016 | A | 156 | $68.442 | A | 43,100 | D | |
| Common StockF2 | Nov 9, 2016 | S | 20,000 | $90.6103 | D | 23,100 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares acquired by the reporting person on October 31, 2016, pursuant to the issuer's Employee Stock Purchase Plan.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $90.18 to $91.305. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.